An approved gene therapy restores vision in children born with a rare form of blindness. There are other gene therapies advancing through clinical trials that could one day treat — and potentially cure — people suffering from devastating diseases like sickle cell, hemophilia, and Duchenne muscular dystrophy, among others.

Overactive bladder is bothersome, but it is most definitely not a devastating disease. Yet Tuesday, the biotech firm Urovant Sciences announced plans to pursue clinical development of a gene therapy to treat people who have this troubling but by no means life-threatening condition.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy